shortterm
ventil
risk
vap
per
day
first
day
ventil
per
day
day
per
day
next
day
although
chronic
tracheostom
ventil
patient
develop
respiratori
infect
risk
greater
develop
tracheobronch
pneumonia
patient
surviv
point
longterm
ventil
rel
low
daili
risk
develop
pneumonia
although
cumul
risk
high
antibiot
use
patient
initi
therapi
aim
broad
spectrum
like
pathogen
thu
empir
infect
pathogen
often
known
therapi
specif
focus
later
basi
result
diagnost
test
case
initi
empir
therapi
must
continu
etiolog
pathogen
identifi
pathogen
recov
term
appropri
refer
use
least
one
antimicrobi
agent
activ
vitro
etiolog
pathogen
term
adequ
includ
appropri
therapi
also
use
agent
correct
dose
right
rout
given
time
fashion
penetr
site
infect
time
appropri
antibiot
therapi
improv
surviv
patient
sever
cap
nosocomi
pneumonia
benefit
evid
patient
otherwis
termin
ill
howev
even
use
correct
agent
patient
recov
ventil
patient
die
spite
microbiolog
appropri
therapi
reflect
degre
antibiot
efficaci
well
reflect
host
respons
capabl
may
part
genet
determin
fact
death
direct
result
infect
patient
death
result
underli
seriou
ill
percentag
death
result
infect
term
attribut
mortal
patient
vap
rate
estim
high
howev
use
time
appropri
antimicrobi
therapi
reduc
attribut
mortal
low
need
initi
therapi
accur
led
frequent
prolong
use
multipl
antibiot
critic
ill
patient
approach
turn
promot
develop
multidrugresist
mdr
pathogen
common
mani
infect
modern
manag
patient
requir
initi
broadspectrum
therapi
follow
narrow
focus
therapi
clinic
cultur
data
becom
avail
deescal
approach
often
accompani
effort
use
shortdur
therapi
numer
guidelin
empir
therapi
cap
nosocomi
pneumonia
develop
sever
caveat
rememb
first
although
current
guidelin
empir
therapi
evid
base
outcom
studi
conduct
demonstr
util
guidelin
improv
mortal
outcom
second
guidelin
must
reevalu
rel
local
pattern
antibiot
suscept
case
cap
emerg
penicillinresist
pneumococcu
communityacquir
methicillinresist
staphylococcu
aureu
mrsa
epidem
viral
ill
influenza
sever
acut
respiratori
syndrom
sar
may
affect
select
initi
therapi
particularli
resist
preval
specif
commun
set
vap
hospit
uniqu
flora
antibiot
suscept
pattern
knowledg
pattern
essenti
antibiot
interfer
growth
bacteria
undermin
integr
cell
wall
interf
bacteri
protein
synthesi
common
metabol
pathway
effect
term
either
bactericid
bacteriostat
broad
categor
may
appli
given
agent
organ
howev
bactericid
antibiot
kill
bacteria
gener
inhibit
cell
wall
synthesi
interrupt
key
metabol
function
organ
agent
type
includ
penicillin
cephalosporin
aminoglycosid
fluoroquinolon
vancomycin
daptomycin
rifampin
metronidazol
bacteriostat
agent
inhibit
bacteri
growth
interfer
cell
wall
synthesi
reli
host
defens
elimin
bacteria
agent
type
includ
macrolid
tetracyclin
sulfa
drug
chloramphenicol
linezolid
clindamycin
use
specif
agent
dictat
suscept
caus
organ
given
locat
individu
antibiot
howev
neutropenia
present
accompani
endocard
mening
use
bactericid
agent
prefer
thu
patient
pneumonia
essenti
choos
bactericid
agent
one
addit
consider
certain
organ
produc
toxin
antibiot
inhibit
protein
synthesi
linezolid
clindamycin
may
advantag
toxinmedi
ill
caus
certain
strain
aureu
compar
cell
wallact
bactericid
antibiot
antimicrobi
activ
specif
agent
often
describ
term
minimum
inhibitori
concentr
mic
minimum
bactericid
concentr
mbc
mic
refer
minimum
concentr
antibiot
inhibit
growth
standard
size
inoculum
lead
visibl
growth
broth
cultur
concentr
bacteria
necessarili
kill
mbc
refer
minimum
concentr
need
caus
decreas
kill
size
standard
inoculum
gener
pathogen
bacteria
kill
concentr
mic
use
defin
sensit
pathogen
specif
antibiot
assumpt
concentr
requir
kill
mic
reach
serum
vivo
howev
term
must
interpret
cautious
patient
pneumonia
mic
data
consid
penetr
agent
lung
tissu
site
infect
thu
agent
achiev
infect
site
concentr
exceed
serum
concentr
efficaci
may
better
predict
mic
data
concern
antimicrobi
resist
led
emerg
newer
term
mutant
prevent
concentr
mpc
mpc
defin
lowest
concentr
antimicrobi
prevent
bacteri
coloni
format
cultur
contain
greater
bacteria
lower
mpc
concentr
spontan
mutant
persist
enrich
among
organ
remain
therapi
clinic
relev
concept
still
uncertain
concentr
antibiot
lung
depend
permeabl
capillari
bed
site
infect
bronchial
circul
degre
protein
bind
drug
presenc
absenc
activ
transport
site
antibiot
lung
lung
relev
site
consid
antibiot
penetr
controversi
concentr
lung
parenchyma
epitheli
line
fluid
cell
macrophag
neutrophil
probabl
import
pneumonia
wherea
bronchial
concentr
may
import
tracheobronch
addit
certain
organ
intracellular
legionella
pneumophila
chlamydophila
pneumonia
organ
macrophag
concentr
may
import
condit
site
infect
may
also
import
agent
inactiv
certain
local
condit
aminoglycosid
reduc
activ
acid
ph
may
present
infect
lung
tissu
addit
certain
bacteria
develop
resist
produc
destruct
enzym
alter
permeabl
outer
cell
wall
chang
target
site
antimicrobi
action
pump
efflux
antimicrobi
interior
cell
condit
high
local
concentr
antimicrobi
agent
may
help
offset
bacteri
resist
mechan
concentr
antibiot
lung
parenchyma
depend
penetr
bronchial
circul
capillari
bronchial
circul
fenestr
endothelium
antibiot
penetr
proport
molecular
size
protein
bind
small
molecul
highli
protein
bound
pass
readili
lung
parenchyma
penetr
bronchial
circul
inflamm
depend
wherea
pulmonari
vascular
bed
nonfenestr
epithelium
inflamm
independ
penetr
best
lipophil
agent
lipophil
drug
includ
chloramphenicol
macrolid
includ
azalid
ketolid
linezolid
clindamycin
tetracyclin
quinolon
trimethoprimsulfamethoxazol
agent
poorli
lipid
solubl
inflamm
depend
entri
epitheli
line
fluid
includ
penicillin
cephalosporin
aminoglycosid
vancomycin
carbapenem
monobactam
volum
distribut
exce
l
find
impli
distribut
outsid
plasma
lipophil
agent
macrolid
quinolon
distribut
extens
bodi
tissu
serum
level
underestim
effect
site
infect
especi
drug
achiev
high
intracellular
concentr
phagocyt
volum
distribut
also
increas
obes
therefor
dose
base
ideal
bodi
weight
may
lead
underdosag
base
dose
hydrophil
antibiot
total
bodi
weight
may
result
overdosag
drug
aminoglycosid
penetr
epitheli
line
fluid
lung
secret
optim
system
therapi
pneumonia
often
less
effect
treatment
bacteremia
reason
agent
studi
deliveri
aerosol
rout
local
administr
antimicrobi
use
therapi
bronchiectasi
especi
set
cystic
fibrosi
treatment
vap
direct
deliveri
antibiot
usual
achiev
nebul
approach
achiev
high
intrapulmonari
concentr
may
without
substanti
system
absorpt
thu
risk
system
toxic
reduc
use
approach
mechan
ventil
patient
somewhat
anecdot
care
studi
propos
patient
either
infecti
tracheobronch
vap
infect
involv
highli
resist
gramneg
bacteria
local
deliveri
antibiot
may
effect
treat
pathogen
erad
system
therapi
mechan
ventil
patient
local
antibiot
administr
instil
nebul
use
prevent
pneumonia
gener
approach
recommend
even
success
concern
emerg
mdr
gramneg
bacteria
patient
subsequ
develop
infect
organ
may
difficult
treat
one
prospect
random
trial
examin
impact
adjunct
use
local
instil
tobramycin
intraven
agent
manag
vap
although
addit
endotrach
tobramycin
improv
clinic
outcom
compar
placebo
microbiolog
erad
significantli
greater
patient
receiv
aerosol
antibiot
spite
data
uncontrol
case
seri
shown
patient
vap
caus
mdr
pseudomona
aeruginosa
acinetobact
speci
aerosol
aminoglycosid
polymyxin
colistin
may
help
adjunct
system
antibiot
one
side
effect
aerosol
antibiot
bronchospasm
induc
antibiot
associ
diluent
present
certain
prepar
special
formul
prepar
tobramycin
aerosol
administr
avail
may
avoid
complic
although
optim
method
administr
aerosol
therapi
unknown
studi
shown
nebul
effect
achiev
uniform
distribut
direct
instil
aerosol
therapi
use
mechan
ventil
patient
must
care
synchron
ventil
cycl
optim
deliveri
devic
yet
defin
anim
model
investig
found
use
ultrason
nebul
place
inspiratori
limb
ventil
circuit
proxim
yconnector
administ
dose
could
retain
lung
tissu
concentr
achiev
given
system
system
absorpt
minim
optim
deliveri
inspiratori
time
may
need
high
ventilatori
cycl
routin
humidif
stop
antibiot
administr
ventil
patient
ventil
may
need
set
tidal
volum
mlkg
humidif
system
use
use
ultrason
nebul
set
deliv
lminut
pharmacokinet
studi
absorpt
distribut
elimin
drug
bodi
inform
use
describ
concentr
serum
pharmacokinet
also
includ
studi
concentr
site
bodi
includ
site
infect
relationship
drug
concentr
pharmacolog
toxic
effect
antibiot
mean
relationship
antibiot
concentr
site
infect
compar
mic
target
organ
pharmacodynam
refer
action
drug
bodi
includ
therapeut
effect
antibiot
kill
bacteria
relat
long
concentr
stay
level
higher
mic
target
organ
timedepend
kill
wherea
agent
effect
relat
peak
concentr
achiev
concentrationdepend
kill
antibiot
kill
time
depend
dose
schedul
chosen
achiev
maxim
time
greater
mic
target
organ
howev
mani
organ
concentr
antibiot
need
greater
mic
dose
interv
possibl
littl
interv
case
carbapenem
antibiot
type
includ
penicillin
cephalosporin
carbapenem
aztreonam
macrolid
clindamycin
rate
kill
satur
antibiot
concentr
exce
four
time
mic
target
organ
continu
infus
studi
optim
timedepend
kill
agent
bacteri
kill
concentr
depend
activ
determin
degre
concentr
achiev
site
infect
size
area
curv
auc
drug
concentr
plot
versu
time
relat
mic
target
organ
altern
action
agent
describ
high
peak
serum
concentr
cmax
relat
organ
mic
classic
agent
type
includ
aminoglycosid
fluoroquinolon
ketolid
also
concentrationdepend
antibiot
type
agent
optim
kill
bacteria
defin
ratio
auc
mic
often
refer
area
inhibit
curv
auic
target
auic
gramneg
bacteria
greater
aminoglycosid
quinolon
studi
shown
efficaci
also
defin
cmaxmic
ratio
aim
target
quinolon
pneumococcu
optim
use
agent
would
entail
infrequ
administr
high
dose
underli
principl
behind
oncedaili
administr
aminoglycosid
oncedaili
aminoglycosid
dose
patient
achiev
high
peak
concentr
maxim
kill
low
trough
concentr
minim
nephrotox
regimen
reli
postantibiot
effect
pae
maintain
efficaci
antibiot
serum
lung
concentr
fall
less
mic
target
organ
antibiot
pae
capabl
suppress
bacteri
growth
even
concentr
fall
less
mic
target
organ
clinic
practic
use
oncedaili
aminoglycosid
dose
variabl
benefit
efficaci
toxic
agent
kill
concentrationdepend
fashion
prolong
pae
wherea
agent
littl
pae
gramneg
bacteria
gener
also
agent
kill
timedepend
fashion
henc
given
sever
time
daili
although
necessari
initi
prompt
accur
antibiot
therapi
patient
sever
pneumonia
initi
therapi
usual
empir
often
imposs
identifi
specif
etiolog
agent
pneumonia
first
diagnos
choic
empir
therapi
base
knowledg
like
etiolog
pathogen
clinic
set
modifi
knowledg
local
pattern
bacteriolog
preval
specif
type
antimicrobi
resist
given
region
specif
hospit
set
american
thorac
societi
infecti
diseas
societi
america
develop
algorithm
initi
empir
therapi
sever
pneumonia
aris
commun
hospit
sever
communityacquir
pneumonia
primari
etiolog
pathogen
sever
cap
pneumococcu
patient
requir
mechan
ventil
treat
cap
treat
possibl
drugresist
streptococcu
pneumonia
drsp
along
like
pathogen
includ
l
pneumophila
organ
treat
includ
haemophilu
influenza
mycoplasma
pneumonia
c
pneumonia
aspir
organ
usual
enter
gramneg
organ
anaerob
aerob
gramneg
bacilli
includ
p
aeruginosa
controversi
whether
enter
gramneg
bacteria
common
cap
identifi
risk
factor
includ
featur
would
reclassifi
affect
patient
hcap
cap
thu
patient
admit
nurs
home
dialysi
center
hospit
previou
day
treat
hcap
algorithm
risk
factor
gramneg
organ
includ
aspir
pulmonari
comorbid
recent
antibiot
therapi
day
past
month
concern
p
aeruginosa
infect
increas
patient
bronchiectasi
malnutrit
human
immunodefici
viru
infect
corticosteroid
therapi
mgday
patient
sever
cap
follow
influenza
anoth
consider
aureu
concern
sever
cap
set
caus
communityacquir
mrsa
patient
cap
admit
intens
care
unit
icu
divid
risk
p
aeruginosa
patient
requir
combin
therapi
monotherapi
recommend
icuadmit
cap
patient
absenc
efficaci
data
singl
agent
set
patient
risk
p
aeruginosa
therapi
select
combin
either
macrolid
quinolon
recommend
includ
ceftriaxon
cefotaxim
ampicillinsulbactam
ceftriaxon
given
g
daili
mg
twice
daili
latter
recommend
sever
pneumococc
infect
especi
associ
mening
patient
requir
addit
either
macrolid
quinolon
possibl
atyp
pathogen
legionella
spp
pneumonia
c
pneumonia
infect
either
sole
caus
part
mix
infect
studi
includ
involv
sever
cap
shown
addit
type
coverag
associ
lower
mortal
rate
regimen
use
recommend
macrolid
intraven
azithromycin
mgday
day
better
toler
erythromycin
recommend
quinolon
moxifloxacin
mgday
regardless
renal
function
levofloxacin
mgday
patient
normal
renal
function
patient
abnorm
renal
function
levofloxacin
dose
adjust
use
initi
start
dose
patient
addit
sever
retrospect
studi
patient
bacterem
pneumococc
pneumonia
demonstr
dual
therapi
includ
combin
macrolid
quinolon
associ
improv
outcom
compar
singleag
therapi
penicillinallerg
patient
therapi
antipneumococc
quinolon
levofloxacin
moxifloxacin
addit
aztreonam
risk
factor
p
aeruginosa
present
patient
treat
two
antipseudomon
agent
addit
coverag
drsp
legionella
effect
antimicrobi
use
type
patient
sever
cap
select
cefepim
piperacillintazobactam
imipenem
meropenem
combin
antipseudomon
quinolon
ciprofloxacin
highdos
levofloxacin
mgday
altern
forego
combin
aminoglycosid
either
azithromycin
nonpseudomon
quinolon
moxifloxacin
penicillinallerg
patient
aztreonam
combin
aminoglycosid
antipneumococc
fluoroquinolon
box
monotherapi
antipneumococc
fluoroquinolon
sever
cap
yet
proven
safe
effect
moxifloxacin
efficaci
cap
even
elderli
patient
patient
sever
cap
studi
although
communityacquir
pneumonia
recoveri
elderli
capri
studi
compar
moxifloxacin
levofloxacin
cap
elderli
patient
cure
rate
moxifloxacin
greater
levofloxacin
patient
studi
mechan
ventil
recent
studi
sever
cap
compar
levofloxacin
combin
ceftriaxoneofloxacin
therapi
equival
clinic
respons
observ
treatment
group
levofloxacin
compar
combin
therapi
howev
patient
shock
exclud
studi
patient
mechan
ventil
treatment
levofloxacin
result
lower
clinic
cure
rate
compar
combin
therapi
current
guidelin
recommend
quinolon
use
sever
cap
use
replac
macrolid
part
combin
regimen
usual
howev
recent
report
use
initi
empir
therapi
fluoroquinolon
sever
cap
associ
increas
shortterm
mortal
odd
ratio
confid
interv
comparison
guidelinerecommend
antimicrobi
regimen
specif
organ
later
recov
cultur
therapi
modifi
focus
previou
caveat
bacterem
pneumococc
pneumonia
kept
mind
addit
patient
histori
contain
certain
epidemiolog
clue
travel
comorbid
ill
anim
exposur
therapi
modifi
cover
suspect
organ
exampl
patient
chronic
obstruct
pulmonari
diseas
treat
h
influenza
moraxella
catarrhali
addit
sputum
gram
stain
obtain
show
gramposit
cocci
cluster
particularli
patient
sever
pneumonia
follow
recent
viral
influenza
infect
therapi
aureu
ad
although
communityacquir
mrsa
common
cap
report
follow
influenza
viral
infect
otherwis
healthi
patient
sever
bilater
necrot
pneumonia
organ
differ
nosocomi
mrsa
occur
previous
healthi
peopl
produc
pantonvalentin
leukocidin
virul
factor
caus
tissu
necrosi
usual
usa
clonal
type
treatment
type
pneumonia
uncertain
vancomycin
alon
may
effect
one
case
seri
suggest
therapi
includ
antibiot
inhibit
toxin
clindamycin
ad
vancomycin
linezolid
use
alon
forego
recommend
therapi
effect
drsp
common
unit
state
pneumococcu
resist
penicillin
mgl
may
account
clinic
isol
unit
state
common
patient
immunocompromis
receiv
antibiot
past
month
penicillin
resist
seen
patient
pneumonia
intermedi
type
high
level
minim
inhibitori
concentr
mgl
observ
may
explain
find
outcom
cap
gener
worsen
presenc
penicillinresist
organ
compar
penicillinsensit
organ
effect
therapi
achiev
ceftriaxon
cefotaxim
probabl
like
effect
cefuroxim
antipneumococc
quinolon
moxifloxacin
levofloxacin
dose
also
effect
legionella
infect
document
quinolon
may
reliabl
therapi
mechan
ventil
patient
sever
cap
consider
given
adjunct
therapi
corticosteroid
three
clinic
situat
may
necessit
approach
first
patient
pneumococc
pneumonia
mening
therapi
corticosteroid
start
antibiot
improv
likelihood
good
neurolog
outcom
second
patient
sever
cap
hypotens
rel
adren
insuffici
common
physiolog
replac
dose
corticosteroid
may
help
final
one
prospect
random
trial
sever
cap
show
improv
outcom
includ
mortal
patient
receiv
continu
infus
lowto
moderatedos
corticosteroid
addit
corticosteroid
use
activ
protein
c
may
help
sever
cap
although
section
adjunct
ventil
therapi
administ
first
dose
antibiot
therapi
within
hour
arriv
hospit
treat
patient
pneumococcu
includ
drsp
legionella
consid
coverag
haemophilu
influenza
enter
gramneg
bacteria
includ
pseudomona
aeruginosa
staphylococcu
aureu
includ
mrsa
atyp
pathogen
mycoplasma
pneumonia
chlamydophila
pneumonia
limit
macrolid
monotherapi
outpati
inpati
risk
factor
drsp
enter
gramneg
bacteria
aspir
sever
ill
use
either
select
macrolid
azithromycin
quinolon
levofloxacin
moxifloxacin
patient
risk
p
aeruginosa
infect
penicillin
allerg
use
antipneumococc
quinolon
plu
aztreonam
risk
p
aeruginosa
infect
use
antipseudomon
plu
either
ciprofloxacin
levofloxacin
combin
aminoglycosid
either
macrolid
antipneumococc
quinolon
levofloxacin
moxifloxacin
penicillin
allerg
use
aztreonam
plu
aminoglycosid
plu
antipneumococc
quinolon
cover
drsp
select
accept
intraven
includ
ceftriaxon
cefotaxim
ertapenem
ampicillinsulbactam
antipseudomon
includ
cefepim
imipenem
meropenem
piperacillintazobactam
administ
quinolon
monotherapi
patient
intens
care
unitadmit
cap
newer
antipneumococc
quinolon
order
decreas
antipneumococc
activ
gemifloxacin
oral
moxifloxacin
oral
intraven
levofloxacin
oral
intraven
vancomycin
linezolid
use
rare
patient
sever
cap
either
mening
vancomycin
sever
necrot
pneumonia
influenza
communityacquir
toxinproduc
mrsa
suspect
use
either
linezolid
alon
consid
ad
clindamycin
vancomycin
document
benefit
minim
patient
receiv
accur
appropri
antibiot
therapi
compar
hospitalacquir
pneumonia
hap
group
includ
patient
vap
sever
nosocomi
pneumonia
requir
mechan
ventil
support
time
sever
infect
patient
risk
infect
group
core
pathogen
also
risk
infect
addit
organ
particularli
mdr
pathogen
base
presenc
risk
factor
although
gener
pattern
appli
patient
bacteriolog
featur
vari
one
hospit
anoth
one
icu
anoth
one
time
period
anoth
therefor
necessari
knowledg
local
microbiolog
data
adapt
treatment
recommend
specif
clinic
set
patient
particularli
acut
respiratori
distress
syndrom
polymicrobi
infect
multipl
bacteri
pathogen
act
synergist
pure
anaerob
pneumonia
uncommon
patient
hap
includ
aspir
risk
factor
latter
popul
enter
gramneg
organ
still
domin
concern
although
fungal
viral
pathogen
caus
hap
situat
rel
uncommon
base
current
data
candida
gener
uncommon
pathogen
common
colon
rare
caus
pneumonia
convers
aspergillu
import
caus
hap
particularli
patient
prolong
hospit
stay
antibiot
corticosteroid
therapi
clinic
suspicion
hap
mechan
ventil
patient
patient
treat
antibiot
unless
suspicion
infect
low
gram
stain
endotrach
suction
aspir
neg
antibiot
choic
either
narrowspectrum
regimen
broadspectrum
regimen
latter
direct
mdr
pathogen
narrowspectrum
approach
use
patient
pneumonia
start
first
day
hospit
risk
factor
mdr
pathogen
present
patient
hcap
patient
includ
hcap
receiv
broadspectrum
therapi
narrowspectrum
therapi
direct
core
pathogen
gener
achiev
singl
agent
option
ceftriaxon
ampicillinsulbactam
ertapenem
levofloxacin
moxifloxacin
ciprofloxacin
patient
allerg
penicillin
quinolon
use
patient
given
combin
clindamycin
aztreonam
patient
risk
factor
mdr
pathogen
therapi
direct
core
pathogen
also
p
aeruginosa
acinetobact
speci
mani
instanc
mrsa
provid
spectrum
coverag
therapi
includ
least
two
often
three
antibiot
recommend
therapi
use
either
aminoglycosid
antipseudomon
quinolon
ciprofloxacin
levofloxacin
combin
antipseudomon
choic
cefepim
ceftazidim
imipenem
meropenem
piperacillintazobactam
choos
among
option
import
use
differ
agent
patient
receiv
previou
day
repeat
use
agent
may
lead
clinic
failur
relat
select
resist
result
recent
exposur
box
concern
mrsa
risk
factor
high
local
preval
presenc
cluster
gramposit
organ
gram
stain
tracheal
aspir
sampl
third
agent
either
linezolid
vancomycin
ad
cultur
data
tracheal
aspir
becom
avail
therapi
sometim
specif
exampl
mrsa
document
ventil
patient
data
suggest
advantag
linezolid
vancomycin
acinetobact
speci
drug
choic
carbapenem
resist
class
antibiot
present
recommend
therapi
colistin
although
tigecyclin
may
becom
option
futur
clinic
data
set
avail
valu
combin
therapi
controversi
gener
strong
data
show
use
aminoglycosid
effect
monotherapi
unless
patient
neutropen
pseudomon
bacteremia
thu
mechan
ventil
patient
given
combin
therapi
major
justif
provid
broad
enough
spectrum
therapi
treat
mdr
pathogen
effect
patient
risk
factor
import
use
correct
dose
antibiot
critic
ill
ventil
patient
pneumonia
base
clinic
trial
data
correct
dose
patient
normal
renal
function
includ
follow
cefepim
g
everi
hour
imipenem
mg
everi
hour
g
everi
hour
meropenem
g
everi
hour
piperacillintazobactam
g
everi
hour
levofloxacin
mgday
ciprofloxacin
mg
everi
hour
vancomycin
mgkg
everi
hour
lead
trough
level
mgl
linezolid
mg
everi
hour
aminoglycosid
mgkgday
gentamicin
tobramycin
mgkg
amikacin
use
antibiot
effect
respons
patient
necessari
implement
deescal
strategi
impli
prompt
use
broadspectrum
empir
therapi
whenev
clinic
suspicion
infect
mdr
pathogen
reason
approach
avoid
delay
therapi
use
broadenough
spectrum
regimen
cover
like
pathogen
howev
avoid
overus
antibiot
key
decis
point
come
day
cultur
clinic
respons
data
becom
avail
becom
possibl
narrow
focu
therapi
case
stop
therapi
altogeth
aim
short
durat
treatment
base
cultur
data
deescal
often
possibl
therefor
aminoglycosid
use
maxim
benefit
may
achiev
day
dual
therapi
aminoglycosid
usual
stop
point
nonresist
gramneg
organ
identifi
therapi
immedi
deescal
singl
agent
drug
shown
effect
critic
ill
mechan
ventil
patient
ciprofloxacin
levofloxacin
imipenem
meropenem
piperacillintazobactam
cefepim
deescal
done
soon
cultur
data
avail
also
done
patient
neg
cultur
even
mdr
pathogen
provid
effect
singl
agent
identifi
sensit
test
result
approach
led
less
total
antibiot
use
instanc
reduc
mortal
anoth
way
use
less
antibiot
shorten
durat
therapi
sever
studi
shown
possibl
treat
vap
effect
day
therapi
provid
initi
therapi
appropri
optim
durat
therapi
infect
caus
p
aeruginosa
mrsa
still
uncertain
prolong
therapi
may
better
shortdur
therapi
absenc
bacteremia
section
adjunct
ventil
therapi
initi
therapi
soon
clinic
suspicion
infect
obtain
lower
respiratori
tract
cultur
tracheal
aspir
protect
brush
bronchoalveolar
lavag
initi
antibiot
therapi
sampl
obtain
bronchoscop
otherwis
cultur
quantit
semiquantit
delay
therapi
purpos
collect
cultur
choos
narrowspectrum
agent
patient
risk
factor
mdr
pathogen
hcap
option
includ
ceftriaxon
ampicillinsulbactam
ertapenem
levofloxacin
moxifloxacin
ciprofloxacin
penicillin
allergi
use
quinolon
combin
clindamycin
aztreonam
choos
broadspectrum
regimen
least
two
drug
patient
risk
factor
mdr
pathogen
use
knowledg
local
microbiolog
guid
choic
use
aminoglycosid
antipneumococc
quinolon
ciprofloxacin
highdos
levofloxacin
plu
antipseudomon
cefepim
ceftazidim
imipenem
meropenem
piperacillintazobactam
concern
mrsa
add
either
linezolid
vancomycin
use
correct
therapi
recommend
dose
recommend
dose
patient
normal
renal
function
cefepim
g
everi
hour
imipenem
mg
everi
hour
g
everi
hour
meropenem
g
everi
hour
piperacillintazobactam
g
everi
hour
levofloxacin
mgday
ciprofloxacin
mg
everi
hour
vancomycin
mgkg
everi
hour
lead
trough
level
mgl
linezolid
mg
everi
hour
aminoglycosid
mgkg
per
day
gentamicin
tobramycin
mgkg
amikacin
choos
empir
therapi
use
agent
class
antibiot
differ
patient
receiv
past
week
drug
choic
acinetobact
infect
carbapenem
colistin
consid
carbapenem
resist
futur
tigecyclin
may
appropri
choic
consid
linezolid
altern
vancomycin
especi
patient
renal
insuffici
receiv
nephrotox
medic
proven
mrsa
ventilatorassoci
pneumonia
adjunct
aerosol
aminoglycosid
use
patient
highli
resist
gramneg
pathogen
system
therapi
continu
hcap
health
careassoci
pneumonia
mdr
multidrug
resist
mrsa
methicillinresist
staphylococcu
aureu
wellcontrol
studi
need
antibiot
therapi
nosocomi
tracheobronch
mechan
ventil
patient
nosocomi
tracheobronch
usual
defin
condit
patient
fever
increas
usual
purul
sputum
posit
endotrach
aspir
cultur
mechan
ventil
absenc
radiograph
pneumonia
patient
usual
infect
p
aeruginosa
mortal
length
stay
may
higher
ventil
patient
without
complic
spite
advers
outcom
remain
uncertain
whether
specif
antimicrobi
therapi
need
anecdot
experi
shown
patient
sign
system
sepsi
therapi
aerosol
antibiot
usual
aminoglycosid
colistin
may
effect
durat
therapi
expect
respons
sever
ill
patient
cap
nosocomi
pneumonia
patient
rapidli
improv
effect
therapi
patient
improv
treat
antibiot
day
wherea
need
care
reevalu
patient
sever
pneumonia
improv
usual
occur
day
thu
becom
time
point
decid
whether
patient
made
appropri
respons
therapi
treatment
failur
sever
cap
occur
patient
present
either
earli
late
studi
clinic
respons
cap
examin
patient
mechan
ventil
studi
focus
improv
symptom
cough
sputum
product
dyspnea
along
abil
take
medic
mouth
afebril
statu
least
two
occas
hour
apart
ventil
patient
serial
measur
oxygen
good
indic
respons
radiograph
improv
usual
lag
behind
clinic
improv
patient
sever
cap
fail
respond
therapi
expect
time
interv
necessari
consid
infect
drugresist
unusu
pathogen
mycobacterium
tuberculosi
bacillu
anthraci
anthrax
coxiella
burnetii
burkholderia
pseudomallei
pasteurella
multocida
endem
fungi
hantaviru
pneumon
complic
lung
abscess
endocard
empyema
noninfecti
process
mimic
pneumonia
bronchiol
obliteran
organ
pneumonia
hypersensit
pneumon
pulmonari
vascul
bronchoalveolar
cell
carcinoma
lymphoma
pulmonari
embolu
evalu
nonrespond
patient
individu
may
includ
comput
tomographi
chest
pulmonari
angiographi
bronchoscopi
occasion
open
lung
biopsi
patient
vap
nosocomi
pneumonia
clinic
improv
also
occur
day
serial
measur
clinic
pulmonari
infect
score
may
best
way
evalu
clinic
respons
clinic
paramet
serial
improv
oxygen
best
measur
good
respons
therapi
usual
occur
day
patient
like
surviv
patient
respond
first
step
check
respiratori
tract
cultur
sure
therapi
activ
pathogen
isol
addit
cultur
diagnost
test
need
rule
infect
unusu
pathogen
fungu
anoth
diagnosi
inflammatori
lung
diseas
anoth
site
infect
pneumonia
complic
central
line
infect
empyema
antibioticinduc
coliti
patient
respond
initi
therapi
chang
antibiot
combin
aggress
diagnost
reevalu
carri
later
day
